Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030­

Market Size & Trends

The global head and neck cancer therapeutics market size was estimated at USD 2.04 billion in 2023 and is projected to grow at a CAGR of 11.8% from 2024 to 2030. The market growth can be attributed to the increasing demand for therapeutics due to the rising incidence of head and neck cancer globally. According to the statistics published by GLOBOCAN in 2020, Head and Neck Squamous Cell Carcinoma (HNSCC) is the seventh most common cancer across the globe. In addition, the rising geriatric population and increasing research & development are anticipated to further propel the market.

Increased demand for therapeutics due to the rising incidence of head and neck cancer globally is driving the market growth. HNSCC originates from squamous cells. This includes areas such as the pharynx, oral cavity, larynx, hypopharynx, nasal cavity, and salivary glands. According to statistics published by GLOBOCAN in 2020, HNSCC is the seventh-most common cancer across the globe. According to an article published in the British Dental Journal in November 2022, there were over 660,000 new cases and about 325,000 deaths due to head & neck tumors globally. There is an increasing prevalence globally due to factors such as rising consumption of alcohol & tobacco, growing adoption of a sedentary lifestyle, and increasing geriatric population. Thus, the growing prevalence is one of the primary factors boosting the demand for therapeutics over the forecast period.

Age is a significant risk factor for developing various types of cancers. There is an increasing prevalence of head and neck malignancy due to rising geriatric population. Aging causes certain conditions, such as chronic inflammation and autoimmune disorders, which increase the risk of developing tumors. According to an article published by Visual Capitalist, in 2022, the number of people aged 65 and above was 771 million, which accounted for about 10% of the population. It is estimated that by 2050, about 16% of the population will be aged 65 and above. Countries with the highest percentage of elderly population are Italy, Japan, and Finland.

There have been many technological advancements in screening procedures for diagnosis purposes and a rise in research to develop new therapies for treating malignancy. The pharmaceutical industry has been focusing on R&D to develop new anticancer drugs. According to Evaluate Pharma, global R&D spending is estimated to increase from USD 238 billion in 2022 to USD 285 billion by 2028. This rising R&D spending by pharmaceutical companies reflects the increasing interest in developing new anticancer drugs.

Many therapies are under trial to understand the biological nature of a new drug. For instance, a multi-institutional clinical trial was conducted to evaluate Ethyol, a radiation protector used to treat tumors. This clinical trial included 36 patients with active head and neck tumors. The patients were treated using radiation therapy with the chemotherapy agent Taxol (paclitaxel), of which 28 patients received Ethyol & 8 received no Ethyol (Amifostine). Results of the study showed that Ethyol allows greater tolerability of chemotherapy in tumors.

Market Concentration & Characteristics

The degree of innovation in the market is high owing to technological advancements and increased research efforts. Pharmaceutical companies are investing heavily in R&D, with global spending expected to rise from USD 238 billion in 2022 to USD 285 billion by 2028, indicating a strong commitment to developing new anticancer drugs. Clinical trials, such as those evaluating Ethyol for enhanced chemotherapy tolerance, demonstrate progress in understanding and treating the disease.

Several players are engaging in mergers & acquisitions to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve competency. For instance, in January 2023, LG Chem completed the acquisition of AVEO Oncology, positioning itself as a leading oncology company with a strong clinical pipeline. The merger aims to accelerate the commercialization of anti-cancer drugs, combining LG Chem's R&D strengths with AVEO's expertise in clinical development and U.S. market presence. This strategic move expands LG Chem's reach, diversifies its pipeline, and enhances its capability to develop and commercialize advanced malignancy therapies.

The impact of regulations on the head and neck cancer therapeutics industry is moderate to high, primarily due to the lengthy processes involved in developing, testing, and approving new treatments. Regulatory frameworks establish standards for clinical trials, influencing the design, conduct, and reporting of studies, affecting the selection and progression of therapies through the pipeline. For instance, the inclusion of epigenetic targets and the exploration of epidrugs in clinical trials for HNSCC are guided by regulatory requirements, ensuring safety and efficacy. These regulations also shape the choice of therapeutic agents, such as DNA methylation agents and antibody-based therapeutics, by setting criteria for their evaluation in clinical settings. In addition, the regulatory environment influences the pace and direction of research, promoting innovation in areas like epigenetic regulation and regulatory cell death mechanisms, which are essential for advancing treatments for HNSCC.

Product substitutes include radiotherapy and surgery. Radiotherapy uses high-energy rays or particles to kill malignancy cells and shrink tumors. Surgery, often combined with other treatments like radiation or chemotherapy, removes cancerous tissue from the body. These alternatives play crucial roles in managing tumors, especially in the early stages, where they can be highly effective.

Significant revenue generation in the market is concentrated within retail, specialty, and hospital pharmacies. These entities excel through their specialized services and expertise in managing complex, high-cost medications, including immunotherapy drugs. Their proficiency in navigating the complexities of specialty drugs, alongside robust relationships with healthcare providers and payers, highlights their crucial role in effectively serving this patient demographic.

Therapy Type Insights

Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period. Immunotherapy offers a novel approach to harness the immune system of the body to combat malignancies. This therapeutic strategy involves the administration of immune checkpoint inhibitors, such as pembrolizumab or nivolumab, which disrupt the mechanisms that tumors exploit to evade immune detection. In addition, companies are investigating novel immunotherapy approaches to treat malignancy. In December 2023, Exelixis, Inc. announced the launch of STELLAR-305, a phase 2/3 trial for investigating the combination of zanzalintinib with pembrolizumab versus pembrolizumab in patients suffering from cancer of head and neck.

Targeted therapy held the second-largest market share in 2023 due to the advancement in the treatment, providing a precision-oriented approach that addresses specific molecular alterations driving tumor growth. Unlike conventional treatments, such as chemotherapy, targeted therapy focuses on disrupting the signaling pathways and proteins implicated in the development & progression of cancer cells. Common molecular targets include Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF).Along with the benefits of targeted therapy for the treatment of head & neck cancer, the active involvement of companies and healthcare organizations is also likely to positively impact the segment growth.  For instance, in March 2023, the FDA granted fast-track designation to RRx-001 for treating head and neck cancer.

Route Of Administration Insights

Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells. Among the notable injectables, immunotherapy drugs such as pembrolizumab and nivolumab stand out. These immune checkpoint inhibitors work by unleashing the immune system of the body to recognize and attack tumor cells. Chemotherapy agents like cisplatin are commonly administered via injection to impede the rapid division of cancer cells. Growing industrial developments in the injectable marketplace are estimated to offer a favorable environment for segment growth during the forecast period. For instance, in April 2020, a strategic partnership between Cue Biopharma and Merck was formed to investigate an injectable combination of KEYTRUDA and CUE-101 for treating HPV and head & neck cancer. Moreover, in May 2021, Hikma Pharmaceuticals PLC announced the launch of Docetaxel injection for a novel treatment for metastatic or recurrent head and neck malignancy.

The oral segment held a significant market share in the market in 2023. Tyrosine Kinase Inhibitors (TKIs) like erlotinib and gefitinib are oral drugs that interfere with cancer cell signaling pathways, impeding growth. In addition, targeted therapies such as afatinib may be administered orally to inhibit specific receptors involved in tumor development. Oral medications contribute to the flexibility of treatment schedules and reduce the need for frequent clinic visits, enhancing patients' overall quality of life. In the evolving landscape of head and neck cancer care, oral medicines continue to be valuable components of personalized & effective treatment strategies.

Distribution Channel Insights

Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.The availability of cancer treatments in retail & specialty pharmacies is crucial for ensuring widespread access to essential medications. Retail pharmacies, widely dispersed across communities, offer convenience for patients to access standard treatments and supportive medications. These pharmacies cater to the immediate needs of patients, providing a range of medications for symptom management and routine care. In addition, market players are partnering with pharmacies to consolidate distribution channels.

Hospital pharmacies is projected to witness a significant growth rate over the forecast period. Hospital pharmacies are integral to the treatment process, especially for inpatients and those undergoing surgeries or specialized interventions. They ensure immediate access to a wide range of medications, including chemotherapy drugs, pain management medications, and supportive therapies. They are equipped to handle emergencies, changes in treatment protocols, and personalized care plans tailored to the unique needs of tumor patients. In addition, hospital pharmacies facilitate seamless collaboration among healthcare providers, enabling a coordinated approach to treatment. The availability of malignancy treatments in hospital pharmacies highlights the importance of these facilities in delivering comprehensive tumor care. The integration of specialized medications within hospital pharmacies contributes to a holistic and patient-focused treatment strategy for individuals battling head & neck malignancy.

Regional Insights

North America head and neck cancer therapeutics market accounted for 44.11% share in 2023.The rising prevalence of head & neck malignancy and the highly advanced healthcare infrastructure are key factors influencing the regional market growth. For instance, according to the Canadian Cancer Society 2023, about 7,900 new head and neck tumor cases were estimated to be diagnosed in 2023 in Canada. The rise in approvals for malignancy therapeutics is anticipated to fuel the market. For instance, in March 2023, Incyte received the U.S. FDA approval for its Incyte PD-1 inhibitor for treating metastatic Merkel Cell Carcinoma (MCC). This tumor type usually occurs as skin nodules on the neck, head, and other body areas exposed to sunlight.

U.S. Head And Neck Cancer Therapeutics Market Trends

The head and neck cancer therapeutics market in the U.S. held the largest market share in the North American region. Increased incidence of head and neck malignancy, recent U.S. FDA approvals for anticancer drugs, and increased awareness about tumor diagnosis and treatments are some of the factors driving the market.

Europe Heal And Neck Cancer Therapeutics Market Trends

The head and neck cancer therapeutics market in Europe accounts for a considerable revenue share due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced healthcare infrastructure, which is anticipated to boost clinical research prospects in the region significantly.

The UK head and neck cancer therapeutics market is expected to grow over the forecast period due to the increasing prevalence of head and neck malignancy and the growing need for therapeutics. Regional players are engaged in developing effective and economical treatment therapies, further fueling market growth in the country.

The head and neck cancer therapeutics market in France is projected to grow at a lucrative rate during the forecast period, owing to the high prevalence of head & neck cancer, well-established healthcare infrastructure, and increased focus on research and development.

Germany head and neck cancer therapeutics market is expected to grow over the forecast period due to the advanced healthcare infrastructure, considerable prevalence of head & neck malignancy, and increasing investments in novel therapies for head & neck cancer, which are expected to have a positive impact.

Asia Pacific Head And Neck Cancer Therapeutics Market Trends

The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms. Other factors contributing to market growth are improving healthcare infrastructure, increasing geriatric population, and rising number of local companies entering the market. Asia Pacific has a large population and a high prevalence of cancer. According to an article published in the South Asian Journal of Cancer in January 2022, an estimated 57.5% of global head and neck tumor cases occur in Asia. Asia is the highest contributor of head and neck cancer cases globally.

China head and neck cancer therapeutics market is expected to grow over the forecast period. China is one of the largest pharmaceutical markets globally in manufacturing. A highly skilled workforce, strong healthcare infrastructure, and a strong & evolving consumer health market are some of the factors playing important roles in the development of the pharmaceuticals sector in the country.

The head and neck cancer therapeutics market in Japan is expected to grow over the forecast period owing to high government spending to curb tumor prevalence. The increase in cancer prevalence can be attributed to rapid growth in the geriatric population; Japan has a median age of 44 years, one of the highest in the world.

Latin America Head And Neck Cancer Therapeutics Market Trends

The head and neck cancer therapeutics market in Latin America has exhibited significant growth in the past few years owing to the increased prevalence of various types of head and neck tumors in the region. Lip, oral cavity, and larynx cancers are highly prevalent in the region.

Brazil head and neck cancer therapeutics market is expected to grow over the forecast period due to the increasing incidence of head & neck cancer and rising awareness about cancer diagnosis & treatments that are driving the market.

MEA Head And Neck Cancer Therapeutics Market Trends

The head and neck cancer therapeutics market in MEA was identified as a lucrative region in this industry. The market in this region witnessed gradual developments in the pharmaceutical industry, with more than 140 locally operational entities. The presence of global manufacturers in the region has boosted the market.

Saudi Arabia head and neck cancer therapeutics market is expected to grow over the forecast period owing to the increased prevalence of head and neck cancer, especially cancer of the lip & oral cavity.

Key Head And Neck Cancer Therapeutics Company Insights

Key players are using existing customer bases in the region to prioritize maintaining high-quality standards and gain high market size access. This strategy is useful for brands that have already built trust in the market. These players are heavily investing in advanced technology and infrastructure, allowing them to process & analyze a large volume of samples efficiently. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.

Cumberland Pharmaceuticals Inc. and Bristol-Myers Squibb Company are some of the emerging market participants. These companies focus on achieving funding support from government bodies and healthcare organizations aided by novel product launches to capitalize on untapped avenues.

Recent Developments

• In September 2023, Pierre Fabre S.A. partnered with Vernalis Research (Subsidiary of HitGen Inc.) to develop oncology drugs and focus on cancer drug discovery.

• In August 2023, Merck & Co., Inc. announced positive results for its candidate in a clinical trial, LEAP-010, which is being investigated for treating metastatic and recurrent head & neck cancer. The company started conducting this trial in collaboration with Eisai.

• In May 2023, Bristol-Myers Squibb Company signed a strategic partnership with The Swallows Head & Neck Cancer Support Charity to provide treatment for patients suffering from cancer.

Head And Neck Cancer Therapeutics Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 2.27 billion
Revenue forecast in 2030	USD 4.43 billion
Growth rate	CAGR of 11.8% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2024 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Therapy type, route of administration, distribution channel, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled	Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Cumberland Pharmaceuticals Inc.; Bristol-Myers Squibb Company; AstraZeneca; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd.
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

 

Global Head And Neck Cancer Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 - 2030. For this study, Grand View Research has segmented the global head and neck cancer therapeutics market report based on therapy type, route of administration, distribution channel, and region.

• Therapy Type Outlook (Revenue, USD Million, 2018 - 2030­)

  • Chemotherapy

  • Immunotherapy

  • Targeted Therapy

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Injectable

  • Oral

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail and Specialty Pharmacies

  • Hospital Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • Kuwait

    • UAE